Antigen Capture Enzyme-Linked Immunosorbent Assay (ELISA) for the Detection of the Novel SARS-CoV-2 in Humans

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is the reason behind the transmission of the recently prevailing disease worldwide and is known as coronavirus disease 19 (COVID-19). Coronavirus was first diagnosed in Wuhan, China 2019, which followed a worldwide spread. Whereas assays associated with the examination of virus molecules only detect the hereditary viral substance in the patient's body. On the other hand, the novel coronavirus requires the diagnosis of high serological parameters to examine specific antibodies of SARS-CoV-2. In this case, the only solution is the -linked immunosorbent assay (ELISA) test based on hunting the antigens. In this technique, the combination of antibodies is derived from the S proteins present in the cells of infected coronavirus patients. By applying these test assays for the COVID-19 patients, it is obvious that the nature of the testing is specific and sensitive. This test allows the detection of serum through seroconverts since the visible emergence of symptoms of SARS-CoV-2 in patients. The major benefit of this method is that it takes less time during the examination. Instead, it deals with the identifications of different antigens found in the human body. These tests play a pivotal role in characterizing introduction and recognize profoundly receptive human donors. Herein, we developed an ELISA assay for the easy detection of SARS-CoV-2 and nucleocapsid protein expression levels as an early tool for this disease.

Keywords: ELISA, Molecular detection, Nucleocapsid protein, RT-PCR, SARSCoV- 2.